Table 3.
Association of treatment with complete remission
| Treatment | All EBA cases | NON-MB-EBA | MB-EBA | Cases |
|---|---|---|---|---|
| Corticosteroid | −a | – | – | 223 | 88 | 30 |
| Dapsone | – | – | – | 110 | 43 | 25 |
| Azathioprine | – | – | ndb | 41 | 11 | 7 |
| Colchicine | – | – | nd | 29 | 15 | 7 |
| Cyclosporine | – | ndc | nd | 30 | 9 | 8 |
| Mycophenolate | – | nd | nd | 18 | 2 | 8 |
| IVIGc | 0.0047 | 0.003 | – | 30 | 11 | 13 |
| Methotrexate | – | nd | nd | 12 | 7 | 3 |
| Cyclophosphamide | – | nd | nd | 10 | 3 | 8 |
| Rituximab | 0.0114 | nd | nd | 16 | 3 | 6 |
The table indicates which single treatment, independent of other medications or procedures, was associated with complete remission both on and off EBA treatment. The column “Cases” indicates the number of patients reported to be treated with the indicated drug for all EBA cases | non-MB EBA | MB EBA. Addition of the later 2 may be different from all EBA cases, as the type of EBA was not specified for all cases. Chi square test was used to calculate possible statistical significance
aNot significant
bnd: not done, because less than 10 treated cases
chigh-dose intravenous immunoglobulin. Only treatments with 10 or more patients were included for statistical analysis. Because of too few reported cases, outcomes for immunoadsorption or immunoapheresis (n = 4), daclizumab (n = 4), extracorporal photopheresis (n = 6) and sulfasalazine (n = 1) were not included in this table. The data on the respective treatment outcomes, is, however, listed in the Additional file 1: Table S1